Punchita Rujirachaivej

Nakhon Nayok, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Enhancing Hemoglobin Bart's hydrops fetalis syndrome prevention: a single-tube multiplex real-time PCR assay for the comprehensive detection of four significant α0-thalassemia deletions (--SEA, --THAI, --CR, and --SA) found in Thailand.

Enhancing Hemoglobin Bart's hydrops fetalis syndrome prevention: a single-tube multiplex real-time PCR assay for the comprehensive detection of four significant α0-thalassemia deletions (--SEA, --THAI, --CR, and --SA) found in Thailand.

Journal: Annals of medicine

Published: July 01, 2026

Simultaneous detection of thalassemia, hemoglobinopathies, and G6PD variants using long-read nanopore sequencing: genetic complexity and heterogeneity in Thailand.

Simultaneous detection of thalassemia, hemoglobinopathies, and G6PD variants using long-read nanopore sequencing: genetic complexity and heterogeneity in Thailand.

Journal: PeerJ

Published: April 07, 2026

Enhanced antitumor efficacy of next-generation B7-H3 chimeric antigen receptor T cells containing CD28, CD137 and CD27 costimulatory domains in multiple myeloma.

Enhanced antitumor efficacy of next-generation B7-H3 chimeric antigen receptor T cells containing CD28, CD137 and CD27 costimulatory domains in multiple myeloma.

Journal: Cytotherapy

Published: July 29, 2025

Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera.

Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera.

Journal: The FEBS journal

Published: August 13, 2024

Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach.

Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach.

Journal: Journal of translational medicine

Published: August 08, 2024

Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.

Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.

Journal: Clinical and experimental medicine

Published: August 30, 2023

Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.

Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 26, 2023

Coinheritance of Hb A2-Melbourne (HBD: c.130G>A) and Hb E (HBB: c.79G>A) in Laos and Simultaneous High Resolution Melt Detection of Hb A2-Melbourne and Hb A2-Lampang (HBD: c.142G>A) in a Single Tube.

Coinheritance of Hb A2-Melbourne (HBD: c.130G>A) and Hb E (HBB: c.79G>A) in Laos and Simultaneous High Resolution Melt Detection of Hb A2-Melbourne and Hb A2-Lampang (HBD: c.142G>A) in a Single Tube.

Journal: Hemoglobin

Published: August 28, 2019

The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome

The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: July 28, 2018

Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.

Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.

Journal: Hematology (Amsterdam, Netherlands)

Published: April 14, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026